Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99

We investigated the use of cytotoxic T-lymphocyte (CTL) epitopes in peptide immunotherapy for glioblastoma. Three peptides (ERBB2, BIRC5 and CD99) were selected based on their peptide-T2 cell binding affinities and combined in a multipeptide cocktail or a branched multipeptide synthesized with mini-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Young-Hee, Tran, Thi-Anh-Thuy, Lee, Hyun-Ju, Jung, Sook-In, Lee, Je-Jung, Jang, Wool-Youl, Moon, Kyung-Sub, Kim, In-Young, Jung, Shin, Jung, Tae-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226601/
https://www.ncbi.nlm.nih.gov/pubmed/27409668
http://dx.doi.org/10.18632/oncotarget.10495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226601/
https://www.ncbi.nlm.nih.gov/pubmed/27409668
http://dx.doi.org/10.18632/oncotarget.10495

Ejemplares similares